skip to main content

Our M&A lawyers are among the most experienced and effective in the world. We represent many of the world's largest publicly traded and privately held companies, as well as leading private equity firms, hedge funds, financial advisors and other financial institutions and investors on their most important merger, acquisitions and takeover transactions.

ADMA Biologics to Acquire Therapy Business from Biotest Pharmaceuticals Corporation

Paul, Weiss is representing ADMA Biologics, Inc. in their agreement to acquire certain manufacturing and therapy-related assets from Biotest Pharmaceuticals Corporation. Upon completion of the transaction, ADMA will be positioned to offer a vertically integrated plasma products and immune globulin platform in the U.S. The transaction is expected to close during the first half of 2017.

ADMA Biologics is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases. Biotest Pharmaceuticals Corporation is a wholly owned subsidiary of Biotest AG, a German global provider of plasma products.

The Paul, Weiss team was led by corporate counsel David Harris and included corporate partners Ariel Deckelbaum, Thomas de la Bastide, David Huntington and Ross Fieldston and counsel Scott Grader and Patricia Vaz de Almeida; real estate partner Peter Fisch; employee benefits partner Andrew Gaines; intellectual property partner Claudine Meredith-Goujon; tax partner David Mayo; environmental counsel William O'Brien; litigation partner Andrew Gordon and counsel Peter Jaffe; and antitrust counsel Marta Kelly.

January 23, 2017

© 2019 Paul, Weiss, Rifkind, Wharton & Garrison LLP

Privacy Policy